About Ubiquitin carboxyl-terminal hydrolase 12
Ubiquitin carboxyl-terminal hydrolase 12 (USP12) is a protein
from Homo sapiens identified by UniProt accession
O75317, 370 residues long.
MolForge cross-references it against 0 known binders and
141 disease associations.
Target properties
| Protein name | Ubiquitin carboxyl-terminal hydrolase 12 |
| UniProt accession | O75317 |
| Gene | USP12 |
| Organism | Homo sapiens |
| Length | 370 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (141)
Diseases linked to this target (Open Targets).
- monocyte count · score 0.46
- creatinine measurement · score 0.35
- serum alanine aminotransferase measurement · score 0.34
- serum gamma-glutamyl transferase measurement · score 0.34
- traffic air pollution measurement · score 0.32
- urate measurement · score 0.28
- glioblastoma multiforme · score 0.23
- breast adenocarcinoma · score 0.23
- ulcerative colitis · score 0.22
- inflammatory bowel disease · score 0.22
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O75317-F1 | alphafold | PREDICTED | 88.39 | — |
Amino-acid sequence (370 residues)
MEILMTVSKF ASICTMGANA SALEKEIGPE QFPVNEHYFG LVNFGNTCYC NSVLQALYFC RPFREKVLAY KSQPRKKESL LTCLADLFHS IATQKKKVGV IPPKKFITRL RKENELFDNY MQQDAHEFLN YLLNTIADIL QEERKQEKQN GRLPNGNIDN ENNNSTPDPT WVHEIFQGTL TNETRCLTCE TISSKDEDFL DLSVDVEQNT SITHCLRGFS NTETLCSEYK YYCEECRSKQ EAHKRMKVKK LPMILALHLK RFKYMDQLHR YTKLSYRVVF PLELRLFNTS GDATNPDRMY DLVAVVVHCG SGPNRGHYIA IVKSHDFWLL FDDDIVEKID AQAIEEFYGL TSDISKNSES GYILFYQSRD
Explore Ubiquitin carboxyl-terminal hydrolase 12 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets